| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Investment loss (gain) from investment in eton | NaN | 0 | NaN | 0 |
| Amortization of operating lease right-of-use assets | NaN | NaN | NaN | 399 |
| Impairment of intangible assets | NaN | 0 | NaN | NaN |
| Net loss | -27,602 | 6,626 | 1,020 | -12,785 |
| Depreciation and amortization of property, plant and equipment and software development costs | 455 | 464 | 490 | 961 |
| Amortization of intangible assets | 5,129 | 4,315 | 4,224 | 8,452 |
| Noncash lease expense | 192 | 188 | 583 | NaN |
| Acquisition of melt pharmaceuticals | NaN | 4,358 | NaN | NaN |
| Deferred income tax | NaN | NaN | NaN | 0 |
| (recovery of) provision for credit losses | -195 | -80 | 208 | 340 |
| Amortization of debt issuance costs and debt discount | 451 | 358 | 1,128 | 2,564 |
| Loss on extinguishment of debt | NaN | 0 | -7,750 | NaN |
| Loss on disposal of equipment | NaN | -13 | NaN | NaN |
| Stock-based compensation | 3,837 | 3,800 | 3,271 | 5,431 |
| Accounts receivable | -9,831 | 33,215 | -1,014 | -37,211 |
| Inventories | 2,973 | 689 | 1,282 | 850 |
| Prepaid expenses and other current assets | -346 | 1,525 | 1,327 | -3,776 |
| Accounts payable, accrued expenses, accrued rebates and copay assistance | 3,377 | 22,441 | -3,040 | -24,009 |
| Accrued payroll and related liabilities | -1,201 | 914 | 2,694 | -2,672 |
| Deferred revenue and customer deposits | -639 | 443 | 254 | 47 |
| Net cash (used in) provided by operating activities | -8,992 | 8,411 | 16,588 | 18,865 |
| Net proceeds on sale of investment in eton pharmaceuticals | NaN | 0 | NaN | 0 |
| Investment in patent and trademark assets | 9 | -22 | -147 | 169 |
| Acquisition of melt pharmaceuticals | NaN | 4,358 | NaN | NaN |
| Purchase of product rights and related patents | NaN | -377 | 162 | NaN |
| Purchase of product rights | -18,000 | NaN | NaN | NaN |
| Purchases of property, plant and equipment | 194 | 341 | 210 | 336 |
| Net cash used in investing activities | -18,203 | -4,730 | -225 | -505 |
| Net proceeds from 8.625 notes payable, net of commissions | 49,000 | 0 | NaN | NaN |
| Net proceeds from public offering | NaN | 0 | NaN | NaN |
| Proceeds from new debt, net of costs | NaN | NaN | 244,375 | NaN |
| Proceeds from public offering of common stock, net of offering costs | NaN | 0 | NaN | NaN |
| Payment of debt issuance costs | 113 | 46 | 1,581 | 0 |
| Proceeds from new debt, net of costs | NaN | 244,375 | NaN | NaN |
| Repayment of notes payable, including exit costs | NaN | NaN | 230,901 | NaN |
| Repayment of notes payable, inclusive of costs | NaN | 230,903 | NaN | NaN |
| Payment of payroll taxes upon vesting of psus, rsus and exercise of stock options | NaN | 5,176 | 7,091 | 12,769 |
| Proceeds from exercise of stock options | 25 | 180 | 162 | 125 |
| Net cash provided by financing activities | 48,912 | -5,044 | 4,964 | -12,644 |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | NaN | -1,363 | NaN | NaN |
| Net change in cash and cash equivalents | 21,717 | -1,363 | 21,327 | 5,716 |
| Cash and cash equivalents, beginning of period | 72,927 | 74,290 | 47,247 | NaN |
| Cash, cash equivalents, end of period | 94,644 | 72,927 | 74,290 | NaN |
HARROW, INC. (HROW)
HARROW, INC. (HROW)